Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Harsha Rohira"'
Autor:
Rohit Vashisht, Anupam Kumar Mondal, Akanksha Jain, Anup Shah, Priti Vishnoi, Priyanka Priyadarshini, Kausik Bhattacharyya, Harsha Rohira, Ashwini G Bhat, Anurag Passi, Keya Mukherjee, Kumari Sonal Choudhary, Vikas Kumar, Anshula Arora, Prabhakaran Munusamy, Ahalyaa Subramanian, Aparna Venkatachalam, S Gayathri, Sweety Raj, Vijaya Chitra, Kaveri Verma, Salman Zaheer, J Balaganesh, Malarvizhi Gurusamy, Mohammed Razeeth, Ilamathi Raja, Madhumohan Thandapani, Vishal Mevada, Raviraj Soni, Shruti Rana, Girish Muthagadhalli Ramanna, Swetha Raghavan, Sunil N Subramanya, Trupti Kholia, Rajesh Patel, Varsha Bhavnani, Lakavath Chiranjeevi, Soumi Sengupta, Pankaj Kumar Singh, Naresh Atray, Swati Gandhi, Tiruvayipati Suma Avasthi, Shefin Nisthar, Meenakshi Anurag, Pratibha Sharma, Yasha Hasija, Debasis Dash, Arun Sharma, Vinod Scaria, Zakir Thomas, OSDD Consortium, Nagasuma Chandra, Samir K Brahmachari, Anshu Bhardwaj
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e39808 (2012)
A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding
Externí odkaz:
https://doaj.org/article/7f5e30f92a504d5a9a73abbdd29ca345
Publikováno v:
Applied Microbiology and Biotechnology. 107:3153-3181
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4e2042b1d75ef62248e980b6357d3ad
https://doi.org/10.1007/s00253-023-12512-5
https://doi.org/10.1007/s00253-023-12512-5
Publikováno v:
International journal of pharmaceutics. 600
Natamycin is the only FDA approved drug that is used as a first line of treatment for fungal keratitis caused by filamentous fungi, however natamycin is known for poor corneal penetration. Cell penetrating peptides (CPPs) are emerging nanocarriers fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b823860fffc48ec00d36ca4722f1444
https://pubmed.ncbi.nlm.nih.gov/33737097
https://pubmed.ncbi.nlm.nih.gov/33737097
Publikováno v:
Proceedings of the 35th European Peptide Symposium.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a8f46d6164ae47c0af85560d719f27
https://doi.org/10.17952/35eps.2018.261
https://doi.org/10.17952/35eps.2018.261
Autor:
Swati Gandhi, Vishal Mevada, Varsha Bhavnani, Aparna Venkatachalam, Nagasuma Chandra, Anurag Passi, Gayathri S, Soumi Sengupta, Swetha Raghavan, Trupti Kholia, Anupam Kumar Mondal, Pankaj Kumar Singh, Samir K. Brahmachari, Debasis Dash, Tiruvayipati Suma Avasthi, Anup Shah, Girish Muthagadhalli Ramanna, Malarvizhi Gurusamy, Balaganesh J, Madhumohan Thandapani, Pratibha Sharma, Harsha Rohira, Arun Sharma, Anshula Arora, Prabhakaran Munusamy, Rohit Vashisht, Kumari Sonal Choudhary, Zakir Thomas, Keya Mukherjee, Ilamathi Raja, Raviraj Soni, Priti Vishnoi, Priyanka Priyadarshini, Shruti Rana, Ashwini G. Bhat, Vinod Scaria, Kaveri Verma, Rajesh Patel, Mohammed Razeeth, Ahalyaa Subramanian, Kausik Bhattacharyya, Salman Zaheer, Lakavath Chiranjeevi, Sweety Raj, Vijaya Chitra, Anshu Bhardwaj, Shefin Nisthar, Meenakshi Anurag, Vikas Kumar, Yasha Hasija, Naresh Atray, Akanksha Jain, Sunil N. Subramanya
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 7, p e39808 (2012)
PLoS ONE, Vol 7, Iss 7, p e39808 (2012)
A decade since the availability of Mycobacterium tuberculosis (Mtb) genome sequence, no promising drug has seen the light of the day. This not only indicates the challenges in discovering new drugs but also suggests a gap in our current understanding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6889ca923e00a1d013c87c3d775feed9
https://pubmed.ncbi.nlm.nih.gov/22808064
https://pubmed.ncbi.nlm.nih.gov/22808064